ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Supplements Reduce Deaths In NCI Studies In China “JNCI”

September 17, 1993

Iniparib Plus Chemo Shows Benefit In Phase II Study

January 28, 2011

NCI Programs:Institute Informs Public About Thyroid Cancer Risk From Fallout.

January 3, 2003

FDA Deputy Commissioner Gottlieb To Return To AEI.

December 15, 2006

DCT To Announce June 1 Guidelines For CREG Program In Cell Kinetics Related To Chemo, Radiotherapy

April 25, 1975

NCI Programs: Institute Renews 10 Center Grants, Provides Complete Grant List.

January 28, 2005